

MolMed announces data presentation at the 58th Annual Meeting of the American Society of Hematology

Milan (Italy), November 17, 2016 – MolMed S.p.A. announces that at the 58th Annual Meeting of the American Society of Hematology (ASH), to be held in San Diego (USA) from December 3 to December 6, 2016, first data on preclinical studies conducted on its proprietary cancer immune-gene therapy project CAR-CD44v6 for leukaemia and solid tumours will be presented, as well as data on Zalmoxis, the first patient-specific cell therapy used in combination with haplo-identical haematopoietic stem cell transplant (haplo-HSCT) in adult patients affected by leukaemia or other high-risk haematological malignancies, including the results of a pair-matched analysis conducted using data of the European Group for Blood and Marrow Transplantation (EBMT) Registry.

Oral presentations schedule

Abstract	Title	Presentation date & time (PT)
997	Monocytes Are Required for Both Optimal Anti-Leukemic Efficacy and the Cytokine Release Syndrome By CAR-T Cells: Lessons from an Innovative Xenotolerant Mouse Model	Monday, December 5, 2016 2:45 PM - 3:00 PM
672	Allogeneic Genetically Modified T Cells as Adjunctive Treatment in Haploidentical Hematopoietic Stem-Cell Transplantation of Adult Patients with High-Risk Hematological Malignancies: A Pair-Matched Analysis from the Acute Leukemia Working Party of EBMT	Monday, December 5, 2016 8:15 AM - 8:25 AM

Poster exhibition schedule

Abstract	Title	Presentation date & time (PT)
4599	Impact of Immune Reconstitution and Graft-Versus-Host Disease on Clinical Outcomes after Treatment with Donor T Cells Transduced to Express the Herpes Simplex Virus Thymidine-Kinase Suicide Gene in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation	Monday, December 5, 2016 6:00 PM - 8:00 PM

The related abstracts are available on the ASH 2016 Meeting website:

<https://ash.confex.com/ash/2016/webprogram/>

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325
info@molmed.com - www.molmed.com

Share capital € 19,841,682.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159

About MolMed

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression prophylaxis, currently in Phase III in high-risk acute leukaemia and granted a Conditional Marketing Authorisation by the European Commission; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the cancer and to the concentration of immune system cells into the tumour mass, currently investigated in a broad clinical programme, involving more than 1000 treated patients; CAR-CD44v6, an immune gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and a local unit at OpenZone, in Bresso (Milan). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI).

For further information:

Laura Villa

Investor Relations & Communication Director

MolMed S.p.A.

telefono: +39 02 21277.205

fax: +39 02 21277.325

e-mail: investor.relations@molmed.com

Press agent

Federico Ferrari

SEC Relazioni Pubbliche e Istituzionali s.r.l.

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: ferrari@secrp.it

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A..